

Marta Marquiã©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2710794/publications.pdf>

Version: 2024-02-01

33
papers

3,307
citations

279778

23
h-index

395678

33
g-index

33
all docs

33
docs citations

33
times ranked

4392
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	4.1	13
3	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
4	Long runs of homozygosity are associated with Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 142.	4.8	6
5	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. <i>Journal of Nanobiotechnology</i> , 2021, 19, 122.	9.1	60
6	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
7	From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1541-1553.	2.6	11
8	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. <i>Study Rationale and Research Protocols. Journal of Alzheimer's Disease</i> , 2021, 83, 1233-1249.	2.6	7
9	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. <i>Pharmaceuticals</i> , 2021, 14, 1057.	3.8	27
10	Managing Clinical Trials for Alzheimer's Disease During the COVID-19 Crisis: Experience at Fundaci3 ACE in Barcelona, Spain. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1805-1813.	2.6	3
11	Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 588872.	3.4	131
12	Dementia Care in Times of COVID-19: Experience at Fundaci3 ACE in Barcelona, Spain. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 33-40.	2.6	38
13	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. <i>Scientific Reports</i> , 2020, 10, 1580.	3.3	22
14	Association between retinal thickness and β -amyloid brain accumulation in individuals with subjective cognitive decline: Fundaci3 ACE Healthy Brain Initiative. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 37.	6.2	24
15	[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. <i>Acta Neuropathologica Communications</i> , 2019, 7, 164.	5.2	33
16	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.8	111
17	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. <i>Scientific Reports</i> , 2019, 9, 8698.	3.3	32
18	Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. <i>Acta Neuropathologica Communications</i> , 2019, 7, 37.	5.2	105

#	ARTICLE	IF	CITATIONS
19	18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. Journal of Alzheimer's Disease, 2018, 62, 1691-1702.	2.6	67
20	Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	3.4	12
21	[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathologica, 2017, 134, 619-628.	7.7	77
22	Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Annals of Neurology, 2017, 81, 117-128.	5.3	174
23	Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathologica Communications, 2017, 5, 75.	5.2	85
24	PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. Neurodegenerative Diseases, 2016, 16, 118-124.	1.4	44
25	Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of Neurology, 2015, 78, 787-800.	5.3	535
26	Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study. Alzheimer's Research and Therapy, 2014, 6, 52.	6.2	29
27	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain, 2013, 136, 2510-2526.	7.6	294
28	Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology, 2013, 80, 85-91.	1.1	149
29	Rapidly Progressive Dementia. Alzheimer Disease and Associated Disorders, 2012, 26, 267-271.	1.3	40
30	Brain amyloid and cognition in Lewy body diseases. Movement Disorders, 2012, 27, 965-973.	3.9	150
31	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.5	125
32	Remote cerebral hematomas in patients treated with intravenous rt-PA. Journal of Neurology, 2010, 257, 1062-1066.	3.6	16
33	123I-MIBG Myocardial Scintigraphy in the Diagnosis of Lewy Body Dementia. Neurologia (English) Tj ETQq1 1 0.784314 rgBT ₁ /Overlook	0.4	